Načítá se...
Clinical utility of ramucirumab in non-small-cell lung cancer
Lung cancer is the leading cause of cancer-related mortality worldwide. Non-small-cell lung cancer (NSCLC) accounts for about 85% of all lung cancer cases and approximately 70% of patients with NSCLC have locally advanced or metastatic disease at presentation. In NSCLC patients with advanced or meta...
Uloženo v:
| Vydáno v: | Biologics |
|---|---|
| Hlavní autor: | |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6659776/ https://ncbi.nlm.nih.gov/pubmed/31413541 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/BTT.S175034 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|